In response to a string of reported illnesses across multiple states, the U.S. Food and Drug Administration (FDA) has launched an investigation into California-based company Diamond Shruumz. The company, known for manufacturing microdosing candies and gummies, has been linked to 12 illnesses and 10 hospitalizations in eight states, including Alabama, Arizona, Indiana, Kentucky, Missouri, Nevada, Pennsylvania, and South Carolina. The FDA, in collaboration with the Centers for Disease Control (CDC) and other partners, is working to determine the cause of these incidents.

Individuals who fell ill after consuming Diamond Shruumz-brand products reported a wide range of severe symptoms, including seizures, central nervous system depression, agitation, abnormal heart rates, hyper/hypotension, nausea, and vomiting, according to the FDA. Fortunately, no deaths have been reported, but the agency is taking these incidents seriously and investigating the potential causes.

The affected products include Microdosing Chocolate Bars, Infused Cones, and Micro Dose and Macro Dose Gummies. Consumers who have purchased these products are strongly encouraged to dispose of them immediately. Additionally, parents and caregivers are urged to check if children or teenagers may possess these items, as the packaging may appeal to these demographics.

Diamond Shruumz-brand products can be found through the company's online wholesale store and in various retailers, including smoke/vape shops and establishments selling hemp-derived products like cannabidiol (CBD) or delta-8 tetrahydrocannabinol (delta-8 THC). However, retailers are instructed not to sell or distribute these products pending further instructions from the FDA.

The FDA is diligently working to identify the cause of the reported illnesses and is considering the appropriate next steps. Updates on the investigation will be provided as they become available. Newsweek reached out to both the FDA and Diamond Shruumz for comment, but there has been no response as of yet.

Microdosing, the practice of taking a fraction of a regular dose of psychedelics instead of a full recreational dose, has gained popularity for its purported benefits in enhancing aspects of daily life such as creativity, mood, concentration, and productivity. However, limited research and lack of regulation make it difficult to determine the exact dosages and potential risks associated with microdosing.

As the investigation continues, the FDA emphasizes the importance of caution and urges consumers to be aware of the potential risks of using these products.